Merck Hit With Complete Response Letter on Potential Sarcoma Drug

The FDA has handed Merck a complete response letter on Taltorvic, a potential maintenance treatment for metastatic soft-tissue and bone sarcomas, calling for additional clinical trials to assess safety and efficacy. Merck will work with the FDA to define potential paths forward for the drug, company spokeswoman Pamela Eisele said.
Washington Drug Letter